Abstract:Abstract: Objective:To investigate the effect of sorafenib on proliferation, chemotaxis and invasion of renal carcinoma cell SW839 through modulating the expression of Y-box binding protein 1(YB1). Methods:Lentivirus mediated YB1 shRNA knockdown vector (pLKO.1-shYB1) was constructed and renal carcinoma cell line with stable YB1 knockdown (SW839-shYB1) was established. SW839 cells were treated with sorafenib in various concentrations. The knockdown efficiency of YB1 and the effect of sorafenib on YB1 expression were confirmed by western blot. The MTT, Transwell chemotaxis and Matrigel invasion assay were used to evaluate the role of YB1 and sorafenib on SW839 cell proliferation, chemotaxis and invasion respectively. Results:Renal cell line SW839-shYB1 with stable YB1 knockdown was successfully constructed. Western blot showed significant decrease of YB1 protein in SW839 shYB1 group compared with SW839 scr and SW839 group (P<0.05). YB1 expression was significantly down regulated in SW839 treated with 4 or 8 μmol/L sorafenib compared with SW839 control group (P<0.05). MTT assay showed the proliferation rate of SW839 was reduced (P<0.05) after the 1, 2 and 3 day of YB1 knockdown (t=6.13, 4.61 and 17.18, respectively) or 8, 12 and 16 μmol/L sorafenib treatment (t=4.04, 7.54 and 16.38, respectively). Transwell results showed that epidermal growth factor (EGF)-induced cell chemotaxis ability in SW839-shYB1 group and sorafenib treated group were decreased compared with control group (t=11.52 and 17.94, P<0.05), invasion ability was also reduced (t=6.64 and 4.83, P<0.05). Conclusion:YB1 may play an important role in modulating SW839 cell proliferation, chemotaxis and invasion. Sorafenib should be able to inhibit the expression of YB1 so as to suppress SW839 cell proliferation, chemotaxis and invasion.